title: Transcatheter arterial chemoembolization with an interventional-CT system for recurrent hepatocellular carcinoma after living donor liver transplantation.
abstract: OBJECTIVE
  The aim of this retrospective study was to evaluate the feasibility and treatment effects of transcatheter arterial chemoembolization (TACE) for recurrent intrahepatic hepatocellular carcinoma (HCC) after liver transplantation.
  
  
  METHODS
  Between March 2007 and December 2012, we treated 8 patients (6 men and 2 women; mean age, 54 years) with recurrent HCC after living donor liver transplantation by TACE using an interventional-CT system. We retrospectively investigated treatment outcomes, complications, and the prognosis in these patients.
  
  
  RESULTS
  Overall, 17 sessions of TACE were performed. A single TACE session was performed in 4 patients while multiple TACE sessions were performed in 4 patients. Anticancer drugs and embolic agents were selectively infused from the right hepatic artery (n=7), left hepatic artery (n=1), A3 (n=1), A5 (n=1), A6 (n=1), A7 (n=2), anterior branch (n=1), posterior branch (n=3), intercostal artery (n=1), and right inferior phrenic artery (n=5). There were no procedure-related complications. Response rate was 50%. The median overall survival from the initial TACE for recurrence of HCC was 12.9 months (95% confidence interval, 5 to 21). The 1-year survival rate was 42.9%.
  
  
  CONCLUSIONS
  TACE with an interventional-CT system could play an important role in the treatment of recurrent HCC after liver transplantation.
authors.forename: Takuji
authors.initials: T
authors.lastname: Yamagami
authors.forename: Rika
authors.initials: R
authors.lastname: Yoshimatsu
authors.forename: Masaki
authors.initials: M
authors.lastname: Ishikawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Kajiwara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Aikata
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Tashiro
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kakizawa
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Toyoda
authors.forename: Hideki
authors.initials: H
authors.lastname: Ohdan
authors.forename: Kazuo
authors.initials: K
authors.lastname: Awai
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D015641:Radiography, Interventional / Q000379:methods*; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013813:Therapy, Computer-Assisted / Q000379:methods*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome